These types of evidence strongly support that the blockade of CD24/Siglec-10 immune checkpoint pathway might provide an effective therapeutic target to improve anti-tumor immunity in the aspect of breast and ovarian cancer hosts. This evidence concerns the gene CD24 and ovarian cancer.